Article
Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 1 Jun 2005
Chakkalakal Joe V, Thompson Jennifer, Parks Robin J, Jasmin Bernard J
Abstract excerpt
Although the molecular defect causing Duchenne/Becker muscular dystrophy (DMD/BMD) was identified nearly 20 years ago, the development of effective therapeutic strategies has nonetheless remained a daunting challenge. Over the years, a variety of different approaches have been explored in an effort to compensate for the lack of the DMD gene product called dystrophin. This review not only presents some of the most...
Topics
- Animals
- Anti-Bacterial Agents
- Dystrophin
- Gene Expression Regulation
- Genetic Therapy
- Genetic Vectors
- Glucocorticoids
- Humans
- Muscular Dystrophy, Duchenne
- Mutation
- Myoblasts
- Myostatin
- Stem Cell Transplantation
- Transforming Growth Factor beta
- Utrophin